A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma

Oncologist

Volumn 16, Issue 6, 2011, Pages 835-843

  Mohammed, Tabraiz A ^a,b   Holen, Kyle D ^b   Jaskula Sztul, Renata ^b   Mulkerin, Daniel ^b   Lubner, Sam J ^b   Schelman, William R ^b   Eickhoff, Jens ^c   Chen, Herbert ^b   Loconte, Noelle K ^b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Histone deacetylase inhibitor; Neuroendocrine tumors; Notch signaling; Pancreatic carcinoid; Valproic acid

Indexed keywords

MESSENGER RNA; NOTCH1 RECEPTOR; OCTREOTIDE; VALPROIC ACID;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPONATREMIA; IN VIVO STUDY; LIVER TOXICITY; MALE; NAUSEA; NEUROPATHY; PANCREAS ISLET CELL CARCINOMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VALPROIC ACID;

EID: 79959582403     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0031     Document Type: Article

References (36)

1. Ansari A, Meeran K, Bloom SR. Classification of Neuroendocrine Tumors. In: Hay I, Wass J. Clinical Endocrine Oncology, Second Edition. Blackwell Publishing, Ltd., 2008:437-432.
2. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. The Oncologist 2008;13:539-547.
3. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994;178:187-211.
4. Pisegna J, Sawicki M. Neuroendocrine Pancreas. In: Haskell CM, Berek JS, eds. Cancer Treatment. Philadelphia: W.B. Saunders, 2001;1065-1081.
5. Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gas-troenteropancreatic neuroendocrine tumors. Digestion 2000;62 Suppl 1:19-26.
6. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80 Suppl 1:3-7.
7. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
8. Pinchot SN, Holen K, Sippel RS et al. Carcinoid tumors. The Oncologist 2008;13:1255-1269.
9. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
10. Kang H, O'Connell JB, Leonardi MJ et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 2007;22:183-189.
11. Lee JE, Evans DB. Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors. Cancer Treat Res 1997;90:227-238.
12. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12 Suppl 2:S111-S114.
13. Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27: 4656-4663.
14. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gas-troenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010;29:19.
15. Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carci-noids. Gastroenterology 2005;128:1717-1751.
16. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-542.
17. Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
18. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-948.
19. Shah MH, Young D, Kindler HL et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111-6118.
20. Ansell SM, Mahoney MR, Green EM et al. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hemato-logic toxicity. Am J Clin Oncol 2004;27:232-235.
21. Kulke MH, Kim H, Clark JW et al. A Phase II trial of gemcitabine for met-astatic neuroendocrine tumors. Cancer 2004;101:934-939.
22. Niccoli P, Raoul J, Bang Y et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). ASCO Meeting Abstracts 2010;28: 4000.
23. Delaunoit T, Van den Eynde M, Borbath I et al. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story? Acta Gastroenterol Belg 2009;72:49-53.
24. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-767.
25. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastroin-test Liver Physiol 2005;289:G636-G642.
26. Kunnimalaiyaan M, Yan S, Wong F et al. Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 2005;138:1137-1142, discussion 1142.
27. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 2005;90:4350-4356.
28. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006;281:39819-39830.
29. Kunnimalaiyaan M, Chen H. Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors. Oncologist 2007;12:535-542.
30. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. The Oncologist 2007;12:942-951.
31. Henry TR. The history of valproate in clinical neuroscience. Psychophar-macol Bull 2003;37 Suppl 2:5-16.
32. Adler JT, Hottinger DG, Kunnimalaiyaan M et al. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growthin pheochromocytoma cells. Surgery 2008;144:956-961, discussion 961-952.
33. Ning L, Greenblatt DY, Kunnimalaiyaan M et al. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. The Oncologist 2008;13:98-104.
34. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
35. Massironi S, Conte D, Sciola V et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 2010;105:2072-2078.
36. Nikou GC, Marinou K, Thomakos P et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008;8:510-519.